

Mini Review

Cause of the Obesity, Type 2 Diabetes and Metabolic Syndrome Epidemics, Vaccine Induced Immune Overload versus Nutrition Overload

John B. Classen*

Classen Immunotherapies, Inc., Manchester, USA

*Corresponding author

John B. Classen, Classen Immunotherapies, Inc., 3637 Rockdale Road, Manchester, MD 21102, USA, Tel: 410-377-8526; Email: classen@vaccines.net

Submitted: 05 May 2017

Accepted: 05 June 2017

Published: 07 June 2017

ISSN: 2333-6692

Copyright

© 2017 Classen

OPEN ACCESS

Keywords

- Obesity; Vaccines, Immunization; Type 2 diabetes; Metabolic syndrome

Abstract

There is an epidemic of obesity, type 2 diabetes, metabolic syndrome and associated conditions. Patients with these conditions often have markers of increased inflammation. Many researchers have published that nutrition overload caused the epidemic of obesity and the associated inflammation which leads to type 2 diabetes and metabolic syndrome. A contrasting view has provided extensive evidence that vaccine induced immune overload has caused an epidemic of inflammation and this inflammation caused epidemics of obesity, type 2 diabetes and metabolic syndrome. The data reviewed in these manuscripts provides proof that immune overload, not nutrition overload has been the major contributing factor for the epidemics and inflammation associated with the epidemics. Several lines of evidence are reviewed including evidence that inflammation precedes obesity in many patients, the lack of inflammation in many obese patients, an epidemic of inflammation in thin patients, and an epidemic of obesity in children under 6 months of age. The failure to control the obesity epidemic is blamed on the focus on nutrition and ignoring the root cause, vaccine induced immune overload. Once a patient has developed metabolic syndrome with type 2 diabetes providers are too frequently subjecting their patients to further immune overload by administering yearly influenza vaccines and many other vaccines. This action makes metabolic syndrome more difficult to reverse. The plan to reduce obesity must be focused on preventing immune overload and not blaming patients for their diet. The epidemic of obesity can be reversed through discontinuation of vaccine practices that result in immune overload.

INTRODUCTION

There is little doubt that there is an epidemic of obesity and related type 2 diabetes and metabolic syndrome in Western Nations. There is also little controversy that in many patients obesity, type 2 diabetes, and metabolic syndrome are closely associated with inflammation. There is however two very different explanations for the epidemics of obesity and diabetes/metabolic syndrome and many have published that the epidemics are caused by nutrition overload and this leads to an increase inflammation. A contrasting view states there is an epidemic of immune overload caused by vaccination that this immune overload is causing the epidemics of obesity and metabolic syndrome.

While both those who were proposing the nutrition overload theory and those supporting immune overload agree that inflammation is important for development of diabetes and other components of metabolic syndrome, there is disagreement as to the extent that obesity is causing inflammation. The different opinions on the origins of the epidemics are based on two different lines of study. The nutrition overload theory was based primarily by studying humans and animals with obesity. The data indicating immune overload is the cause of the epidemics was derived from broad population studies of initially healthy babies and studying their responses to vaccines. For example nutrition overload does

not explain the obesity epidemic in children 6 months of age who don't drink many sodas, don't eat a lot of fried foods and have never been very active. Recent data from a Massachusetts HMO showed a 73% increase in overweight infants under 6 months of age from 1980 to 2001 [1]. By contrast immune overload caused by the large increase in childhood immunizations can explain this observation. This paper reviews some of the key weaknesses to the theory that nutrition overload caused the epidemics of obesity and metabolic syndrome. This paper also reviews the evidence that immune overload is causing the epidemics.

THEORY THAT NUTRITION OVERLOAD AND OBESITY CAUSE INFLAMMATION

Numerous review papers have been published describing the theory of nutrition overload as the cause of obesity and the associated inflammation [2-4]. According to its proponents, over eating causes a chain of events that leads to inflammation and then metabolic syndrome. There are several prevailing explanations on how obesity induces inflammation [2,5]. According to one theory free fatty acids can activate the immune cells *in vitro* [6] and it has been suggested fat cells in obese patients may produce more free fatty acids [7]. However it is noted that in weight loss, free fatty acids are released but weight loss does not increase the risk of metabolic syndrome. The mechanism by which obesity causes increases in free fatty acids is unclear. Another theory to

explain the association between inflammation and obesity is that fat cells produce TNF [8] but the evidence that obesity causes more TNF production and this leads to inflammation is not well established.

Another proposed mechanism of obesity inducing inflammation involves adiposities attracting macrophages and the macrophages releasing inflammatory mediators. The presence of activated macrophages in the adipose tissue of some obese patients is clearly documented, but the triggers are less clear. One theory [9,10] states that enlarging fat cells need more blood vessels and this leads to hypoxia. Hypoxia causes fat cells to release factors that stimulate macrophages. The theory is intriguing, but lacks solid evidence, and is not unique to fat cells. Exercise induces hypoxia as well and leads to increased blood vessels in hypertrophied muscles. However exercise is not associated with increased risk of developing inflammatory diseases including diabetes, in fact the opposite. Furthermore, as discussed below, many obese individuals don't have inflammation so the theory does not consistently hold true.

Another theory [10] states that fat cell derived adipokine production causes inflammation. An example is leptin, a known immune stimulant. There are multiple other hormones that are secreted by adipocytes and many are known to modulate the immune system. These include IL-6 [11,12], resistin [13], retinol-binding protein4 (RBP-4) [14], omentin [15], chemerin [16-18], pro- granulin [19], and monocyte chemoattractant protein-1 (MCP-1) [20-22]. However there is no clear data this theory is true, in particular there is no clear data that obesity causes increases in adipokine activity.

INFLAMMATION PRECEDES DEVELOPMENT OF OBESITY AND METABOLIC SYNDROME

In contrast to the belief that obesity is causing inflammation there is data that inflammation precedes the development of obesity and causes obesity. Ding [23] showed that inflammation preceded the development of obesity in mice. Frazier [24] also found evidence that inflammation preceded obesity in animal models. Research suggests CRP levels in children are predictive of adult obesity [25]. Furthermore it has been shown that CRP levels predict future weight changes [26]. Data has been published showing a genetic link between a genetic variant of CRP and fat mass [27]. A review article [28] published evidence that gut inflammation preceded and caused obesity. A study on Finnish middle age men [29] found men with elevated CRP concentrations had higher age-adjusted risk of developing metabolic syndrome. A study of men and women in Mexico [30] found women with elevated CRP in the highest tertile had an increased relative risk of developing metabolic syndrome.

OBESITY DOES NOT CONSISTENTLY CAUSE INFLAMMATION

Additional evidence against obesity as the cause of epidemic of inflammation is the fact that obesity routinely occurs in the absence of inflammation. Patients with a primary Cushingoid condition are obese and immune suppressed but don't have an inflammatory condition. There are multiple papers written about metabolic "healthy" obese populations versus metabolic "unhealthy" obese populations [31]. Metabolic healthy obese

patients have satisfactory insulin sensitivity, and glucose control. Published estimates vary between 20-30% of the obese population are metabolically healthy depending on the study. The difference between studies is based in part on the criteria for defining metabolic healthy versus unhealthy [32-36]. One study found that difference between healthy and unhealthy obese women is that the healthy population had low CRP levels indicating low levels of inflammation [37]. In a second study [38] logistic regression analysis was used to show metabolically healthy obese patients had lower levels of several inflammatory markers than those with obesity that were not metabolically healthy: complement component 3 (odds ratios [ORs], 2-3.5), IL-6 (ORs, 1.7-2.9), plasminogen activatorinhibitor-1 (ORs, 1.7-2.9), and white blood cells (ORs, 2.1-2.5).

INFLAMMATION EPIDEMIC IN THE THIN

Another line of support that inflammation precedes obesity is the finding that inflammation also occurs in thin individuals. There is a well documented epidemic of inflammation and inflammatory conditions in thin individuals in Western countries. This epidemic of inflammation indicates that obesity is not the cause of inflammation in a large group of individuals that are not obese. This observation is important because it is unlikely that there is one cause for an epidemic of inflammation in thin individuals and a second and different cause of an epidemic of inflammation in obese individuals.

NAHME III data from the US children 8-16 year old from 1988-1994 [39], shows elevated CRP was present in children of all BMI quintiles. While there are a higher percentage of obese patients with elevated CRP, the Odds Ratios compared to normal weight children was not great. Elevated CRP was 3.74 times more prevalent in overweight males and 3.17 times in overweight women. Researchers have found substantial overlap in inflammation in nonhealthy obese, healthy obese, and nonhealthy non-obese [38,40]. There is a clear epidemic of type 1 diabetes in children, an autoimmune/inflammatory condition [41]. Type 1 diabetes is associated with thinner populations [42]. These facts do not support the theory that the epidemic of obesity is causing the epidemic of inflammation associated with it but is consistent with an epidemic of inflammation that can cause obesity in certain genotypes.

IMPORTANCE OF GLUCOCORTICOIDS IN DETERMINING WEIGHT

Glucocorticoid production is one of the most important, if not most important factors in determining a person's weight, yet this parameter is rarely measured in obesity studies. Untreated patients with Cushing's disease are almost always obese, while untreated patients with Addison's disease are almost always thin. If one takes an obese patient with Cushing's disease and starves the patient, the patient will lose weight. However it is cortisol excess, not nutrition overload that causes patients with Cushing's disease to be obese. One can titrate the weight of a patient with Addison's disease by titrating the amount of glucocorticoids a patient is given. Prolonged administration of high doses of glucocorticoid steroids will cause patients to develop obesity, hypertension, and dyslipidemia and insulin resistance.

Alterations in the activity of genes responsible for

glucocorticoid metabolism can also affect the risk of metabolic syndrome. Published data has shown evidence that activation of cortisol as a result of increased enzymatic activity of 11-beta hydroxysteroid dehydrogenase type 1 may increase the risk of components of metabolic syndrome [43,44]. It has been suggested that children from Sardinia, who have a high prevalence of conditions that cause decreased cortisol activity [45], glucose-6 phosphate dehydrogenase deficiency and thalassemia, had the lowest levels of childhood obesity in Italy but the highest rates of type 1 diabetes [46].

INFLAMMATION IS A MAJOR DRIVER IN GLUCOCORTICOID PRODUCTION AND CAN CAUSE OBESITY

Because of the strong ability of glucocorticoid steroids to cause obesity, agents that increase glucocorticoid activity can cause obesity. Inflammation is a strong activator of glucocorticoid activity and thus has the potential to cause obesity. Both IL-1 [47,48] and IL-6 [49-51] enhance cortisol release and thus have the potential to cause obesity and metabolic syndrome. IL-6 has been associated with the development of metabolic syndrome [52,53]. In addition IL-6 has been directly associated with the development of diabetes [54], insulin resistance [55] and altered lipid levels [56-58].

Hyperactive glucocorticoid activity induces fat gain especially in the omentum and visceral region as opposed to the periphery. This phenomenon has been explained by the ability of visceral adipocyte to convert inactive corticosterone to cortisol [59]. This explains why abdominal obesity is more strongly associated with inflammatory markers than BMI or total body fat [61-63].

VACCINES INDUCED IMMUNE OVERLOAD AS THE CAUSE OF THE OBESITY EPIDEMIC

There is strong evidence that vaccine induced immune overload is causing the epidemic of obesity. The central thesis is that vaccine induced immune overload causes many different manifestations. Obesity and metabolic syndrome are just a few of the manifestations. Other manifestations linked to vaccine induced immune overload include type 1 diabetes [64], multiple different autoimmune diseases, allergies, asthma [65] and autism [66]. The identification of a single cause of inflammation with multiple different manifestation including type 1 diabetes and obesity is a more traditional and logical explanation than hypothesizing separate causes for each inflammatory condition.

Previous publications have shown that an increase vaccine induced immune overload has caused an epidemic of both type 1 [64,67-69] and type 2 diabetes/metabolic syndrome [46,70-72]. Data indicates vaccine recipients who produce low levels of cortisol tend to develop type 1 diabetes while vaccine recipients who produce higher levels of cortisol tend to develop type 2 diabetes and metabolic syndrome [65].

Immunization causes both short term and long term immune stimulation. Multiple papers have studied short term cytokine release following immunization. The acellular diphtheria tetanus pertussis vaccine causes the release of IL-6 [73] while the DT-Polio-Typhim vaccine stimulates IL-6 production [74]. Immunization with the DTwP vaccine but not the DTaP vaccine

increases IL-6 levels at 2 days post immunization [75]. Research have also found that the influenza vaccine stimulated release of IL-6 and IL-10 [76] and the influenza and pneumococcal vaccine caused rises in CRP [77] over the short term. Long term vaccine induced inflammation has been demonstrated by researchers in France. These scientists have linked aluminum adjuvants in vaccines to prolonged activation of macrophages (lasting possibly decades) and shown the adjuvants cause an inflammatory condition called myofasciitis [78,79].

It is well established that immunization of children can increase cortisol levels at least in the short term [80-87]. Furthermore there is a clear racial difference in cortisol production that mirrors the propensity to develop type 1 versus type 2 diabetes. Caucasian children [6] produce much less cortisol following immunization than Japanese children [88]. The finding explains why the discontinuation of school age BCG immunization was followed by a decreases of type 1 diabetes occurred in a population of Caucasian children [68] but a decreases in type 2 diabetes occurred in Japanese children [72].

CONCLUSION

Both nutrition overload and immune overload have been blamed for the epidemics in obesity, inflammation, type 2 diabetes, and metabolic syndrome. The data reviewed in these manuscripts provides proof that immune overload, not nutrition overload has been the major contributing factor for the epidemics. The plan to reduce obesity must be focused on preventing immune overload and not blaming patients for their diet. The medical industry must take ownership for causing of the epidemics through the inappropriate recommendations and gross over utilization of vaccines. Once a patient has developed metabolic syndrome with type 2 diabetes providers are too frequently subjecting their patients to further immune overload by administering yearly influenza vaccines and many other vaccines. This action makes metabolic syndrome more difficult to reverse. The epidemics of obesity and metabolic syndrome can be reversed through discontinuation of medical vaccine practices that result in immune overload.

REFERENCES

1. Kim J, Peterson KE, Scanlon KS, Fitzmaurice GM, Must A, Oken E, et al. Trends in overweight from 1980 through 2001 among preschool-aged children enrolled in a health maintenance organization. *Obesity* (Silver Spring). 2006; 14: 1107-1112.
2. Donath MY, Dalmas É, Sauter NS, Böni-Schnetzler M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. *Cell Metab*. 2013; 17: 860-872.
3. Skinner AC, Steiner MJ, Henderson FW, Perrin EM. Multiple markers of inflammation and weight status: cross-sectional analyses throughout childhood. *Pediatrics*. 2010; 125: 801-809.
4. Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H. Low-grade inflammation, obesity, and insulin resistance in adolescents. *J Clin Endocrinol Metab*. 2007; 92: 4569-4574.
5. Van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. *Neth J Med*. 2013; 71: 174-187.
6. Boni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, Prazak R, et al. Free fatty acids induce a proinflammatory response in islets

- via the abundantly expressed interleukin-1 receptor I. *Endocrinology*. 2009; 150: 5218-5229.
7. Kosteli A, Sagaru E, Haemmerle G, Martin JF, Lei J, Zechner R, et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. *J Clin Invest*. 2010; 120: 3466-3479.
 8. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science*. 1993; 259: 87-91.
 9. Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW, DeFuria J, Jick Z, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. *Diabetes*. 2007; 56: 2910-2918.
 10. De Heredia FP, Gomez-Martinez S, Marcos A. Chronic and degenerative diseases Obesity, inflammation and the immune system. *Proc Nutr Soc*. 2012; 71: 332-338.
 11. Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. *Obes Rev*. 2008; 9: 20-29.
 12. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science*. 2008; 322: 1539-1543.
 13. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. *Nature*. 2001; 409: 307-312.
 14. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature*. 2005; 436: 356-362.
 15. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. *Am J Physiol Endocrinol Metab*. 2006; 290: 1253-1261.
 16. Goralski KB, Mc Carthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. *J Biol Chem*. 2007; 282: 28175-28188.
 17. Bozaoglu K, Bolton K, Mc Millan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. *Endocrinology*. 2007; 148: 4687-4694.
 18. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. *FEBS Lett*. 2008; 582: 573-578.
 19. Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. *Cell Metab*. 2012; 15: 38-50.
 20. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *J Clin Invest*. 2006; 116: 1494-1505.
 21. Tateya S, Tamori Y, Kawaguchi T, Kanda H, Kasuga M. An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. *Endocrinology*. 2010; 151: 971-979.
 22. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, et al. Over expression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. *J Biol Chem*. 2006; 281: 26602-26614.
 23. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NMJ, Magness S, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. *PLoS One*. 2010; 5: 1-13.
 24. Frazier TH, DiBaise JK, Mc Clain J. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. *J Parenter Enteral Nutr*. 2011; 35: 14-20.
 25. Juonala M, Juhola J, Magnussen CG, Wurtz P, Viikari JSA, Thomson R, et al. Childhood environmental and genetic predictors of adulthood obesity: the cardiovascular risk in young Finns study. *J Clin Endocrinol Metab*. 2011; 96: 1542-1549.
 26. Barzilay JI, Forsberg C, Heckbert SR, Cushman M, Newman AB. The association of markers of inflammation with weight change in older adults: the Cardiovascular Health Study. *Int J Obes (Lond)*. 2006; 30: 1362-1367.
 27. Bochud M, Marquant F, Marques-Vidal PM, Vollenweider P, Beckmann JS, Mooser V, et al. Association between C-reactive protein and adiposity in women. *J Clin Endocrinol Metab*. 2009; 94: 3969-3977.
 28. Ding S, Lund PK. Role of intestinal inflammation as an early event in obesity and insulin resistance. *Curr Opin Clin Nutr Metab Care*. 2011; 14: 328-333.
 29. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. *Diabetologia*. 2004; 47: 1403-1410.
 30. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. *Diabetes Care*. 2002; 25: 2016-2021.
 31. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prodhomme D, et al. The metabolically healthy but obese individuals presents a favorable inflammation profile. *J Clin Endocrinol Metab*. 2005; 90: 4145-4150.
 32. Pataky Z, Bobbioni-Harsch E, Golay A. Open questions about metabolically normal obesity. *Int J Obes (Lond)*. 2014; 34: 18-23.
 33. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? *J Clin Endocrinol Metab*. 2004; 89: 2569-2575.
 34. Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? *Diabetes Metab*. 2004; 30: 569-572.
 35. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). *J Clin Invest*. 1997; 100: 1166-1173.
 36. Wildman RP, Muntner P, Reynolds K, Mc Ginn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). *Arch Intern Med*. 2009; 169: 1617-1624.
 37. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Homme DP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. *J Clin Endocrinol Metab*. 2005; 90: 4145-4150.
 38. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? *J Clin Endocrinol Metab*. 2013; 98: 1610-1619.
 39. Visser M, Bouter LM, Mc Quillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. *Pediatrics*. 2001; 107: 13.
 40. Rhee EJ, Lee MK, Kim JD, Jeon WS, Bae JC, Park SE. Metabolic health is a more important determinant for diabetes development than simple

- obesity: a 4-year retrospective longitudinal study. *PLoS One*. 2014; 9: 98369.
41. Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. *Lancet*. 2000; 355: 873-876.
 42. Classen JB. Italian pediatric data support hypothesis that simultaneous epidemics of type 1 diabetes and type 2 diabetes/metabolic syndrome/obesity are polar opposite responses (i.e symptoms) to a primary inflammatory condition. *JPEM*. 2011; 24: 455-456.
 43. Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. *Ann N Y Acad Sci*. 2006; 1083: 165-184.
 44. Sandeep TC, Andrew R, Homer NZM, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. *Diabetes*. 2005; 54: 872-879.
 45. Siniscalco M, Bernini L, Filippi G, Latte B, Khan M, Piomelli S, et al. Population genetics of hemoglobin variants, thalassemia and glucose-6-phosphate dehydrogenase deficiency, with particular reference to the malaria hypothesis. *Bull World Health Organ*. 1966; 34: 379-393.
 46. Rey AD, Klusman I, Besedovsky HO. Cytokines mediate protective stimulation of glucocorticoid output during autoimmunity, involvement of IL-1. *Am J Physiol*. 1998; 275: 1146-1151.
 47. Angeli A, Masera RG, Sartori ML, Fortunati N, Racca S, Dovio A, et al. Modulation by cytokines of glucocorticoid action. *Ann N Y Acad Sci*. 1999; 876: 210-220.
 48. Bethin KE, Voght SK, Muglia LJ. Interleukin-6 is an essential, corticotropin-releasing-hormone-independent stimulator of the adrenal axis during immune system activation. *Proc Natl Acad Sci USA*. 2000; 97: 9317-9322.
 49. Turnbull AV, Prehar S, Kennedy AR, Little RA, Hopkins SJ. Interleukin-6 is an afferent signal to the hypothalamo-pituitary-adrenal axis during local inflammation in mice. *Endocrinology*. 2003; 144: 1894-1906.
 50. Vallières L, Rivest S. Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. *Endocrinology*. 1999; 140: 3890-3903.
 51. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. *Diabetologia*. 1997; 40: 1286-1292.
 52. Hristova M, Aloe L. Metabolic syndrome--neurotrophic hypothesis. *Med Hypotheses*. 2006; 66: 545-549.
 53. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA*. 2001; 286: 327-334.
 54. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. *Diabetes*. 2002; 51: 3391-3399.
 55. Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. *J Clin Endocrinol Metab*. 2003; 88: 3005-3010.
 56. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. *Endocrinology*. 1995; 136: 2143-2149.
 57. Lyngso D, Simonsen L, Bülow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. *J Physiol*. 2002; 543: 379-386.
 58. Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in splanchnic and adipose tissue. *J Clin Endocrinol Metab*. 2002; 543: 379-386.
 59. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? *Lancet*. 1997; 349: 1210-1213.
 60. Festa A, D'Agostino R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, et al. The relation of body fat mass and distribution to markers of chronic inflammation. *Int J Obes Relat Metab Disord*. 2001; 25: 1407-1415.
 61. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. *Diabetes Res Clin Pract*. 2005; 69: 29-35.
 62. Hermsdorff HH, Zulet MA, Puchau BV. Central adiposity rather than total adiposity measurements are specifically involved in the inflammatory status from healthy young adults. *Inflammation*. 2011; 34: 161-170.
 63. Lapice E, Maione S, Patti L, Cipriano P, Rivelles AA, Riccardi G, et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. *Diabetes Care*. 2009; 32: 1734-1736.
 64. Classen JB, Classen DC. Clustering of cases of insulin dependent diabetes (IDDM) occurring three years after hemophilus influenza B (HiB) immunization support causal relationship between immunization and IDDM. *Autoimmunity*. 2002; 35: 247-253.
 65. Classen JB. Review of vaccine induced immune overload and the resulting epidemics of type 1 diabetes and metabolic syndrome, emphasis on explaining the recent accelerations in the risk of prediabetes and other immune mediated diseases. *Mol Genetic Med*. 2014; 1: 25.
 66. Classen, JB. Prevalence of autism is positively associated with the incidence of type 1 diabetes, but negatively associated with the incidence of type 2 diabetes, implication for the etiology of the autism epidemic. *Open Access Scientific Reports*. 2013; 2: 679.
 67. Classen DC, Classen JB. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. *Infect Dis Clin Pract*. 1997; 6: 449-454.
 68. Classen JB, Classen DC. Clustering of cases of IDDM occurring 2- 4 years after vaccination is consistent with clustering after infections and progression to IDDM in autoantibody positive individual. *J Pediatr Endocrinol Metab*. 2003; 16: 495-508.
 69. Classen JB, Classen DC. Vaccines and the risk of insulin-dependent diabetes (IDDM): potential mechanism of action. *Med Hypotheses*. 2001; 57: 532-538.
 70. Classen JB. Evidence childhood epidemics of type 1 and type 2 diabetes are opposite extremes of an immune spectrum disorder induced by immune stimulants. Role of race and associated cortisol activity as a major determining factor of diabetes. *Diabetes & Metabolic Syndrome: Clin Res Rev*. 2009; 3: 67-69.
 71. Classen JB. Type 1 versus type 2 diabetes/metabolic syndrome, opposite extremes of an immune spectrum disorder induced by vaccines. *Open Endocrinol J*. 2008; 2: 9-15.
 72. Classen JB. Discontinuation of BCG vaccination precedes significant drop in type 2 diabetes in Japanese children. Role of inflammation and cortisol activity as a cause of type 2 diabetes. *Open Endocrinol J*. 2008; 2: 1-4.
 73. Rowe J, Yerkovich ST, Richmond P, Suriyaarachchi D, Fisher E, Feddema L, et al. Th-2 local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4 to 6 year old children. *Infect Immun*. 2005; 73: 8130-8135.

74. El Yousfi M, Mercier S, Breuillé D, Denis P, Papet I, Mirand PP, et al. The inflammatory response to vaccination is altered in the elderly. *Mech Ageing Dev.* 2005; 126: 874-881.
75. Pourcyrous M, Korones SB, Crouse D, Bada HS. Interleukin-6, C-reactive protein, and abnormal cardiorespiratory responses to immunization in premature infants. *Pediatrics.* 1998; 101: 3-8.
76. Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM. Cytokine production after influenza vaccination in a healthy elderly population. *Vaccine.* 1998; 16: 1722-1731.
77. Posthouwer D, Voorbij HA, Grobbee DE, Numans ME, van der Bom JG. Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. *Vaccine.* 2004; 23: 362-365.
78. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. *Brain.* 2001; 124: 1821-1831.
79. Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, et al. Central nervous system disease in patients with macrophagic myofasciitis. *Brain.* 2001; 124: 974-983.
80. Oken E, Kasper DL, Gleason RE, Adler GK. Tetanus toxoid stimulation of the hypothalamic-pituitary-adrenal axis correlates inversely with the increase in tetanus toxoid antibody titers. *J Clin Endocrinol Metab.* 1998; 83: 1691-1696.
81. Catania A, Airaghi L, Manfredi G, Zanussi C. Hormonal response during antigenic challenge in normal subjects. *Int J Neurosci.* 1990; 51: 295-296.
82. Gunnar MR, Brodersen L, Krueger K, Rigatuso J. Dampening of adrenocortical responses during infancy: Normative changes and individual differences. *Child Dev.* 1996; 67: 877-889.
83. Lewis M, Ramsay DS. Stress reactivity and self-recognition. *Child Dev.* 1997; 68: 621-629.
84. Ramsay D, Lewis M. Reactivity and regulation in cortisol and behavioral responses to stress. *Child Dev.* 2003; 74: 456-464.
85. Lewis M, Thomas D. Cortisol release in infants in response to inoculation. *Child Dev.* 1990; 61: 50-59.
86. Lewis M, Ramsay DS. Developmental change in infants' responses to stress. *Child Dev.* 1995; 66: 657-670.
87. Ramsay DS, Lewis M. Developmental change in infant cortisol and behavioral response to inoculation. *Child Dev.* 1994; 65: 1491-1502.
88. Lewis M, Ramsay DS, Kawakami K. Differences between Japanese infants and Caucasian American infants in behavioral and cortisol response to inoculation. *Child Dev.* 1993; 64: 1722-1731.
89. Barzilay JI, Forsberg C, Heckbert SR, Cushman M, Newman AB. The association of markers of inflammation with weight change in older adults: the Cardiovascular Health Study. *Int J Obes (Lond).* 2006; 30: 1362-1367.

Cite this article

Classen JB (2017) Cause of the Obesity, Type 2 Diabetes and Metabolic Syndrome Epidemics, Vaccine Induced Immune Overload versus Nutrition Overload. *J Endocrinol Diabetes Obes* 5(3): 1107.